loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Golidocitinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Golidocitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL
    Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

    20 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-302176781.html

    PR NEWSWIRE
    20 Jun 2024
    Share Share
    Dizal's Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL
    Dizal's Golidocitinib Trial Demonstrates Durable Benefits for r/r PTCL

    10 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizals-golidocitinib-pivotal-trial-demonstrates-superior-and-durable-clinical-benefits-for-patients-with-rr-ptcl-in-oral-presentation-at-2023-ash-302010729.html

    PR NEWSWIRE
    10 Dec 2023
    Share Share
    Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL
    Golidocitinib Granted Priority Review by NMPA for the Treatment of r/r PTCL

    21 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/golidocitinib-granted-priority-review-by-china-nmpa-for-the-treatment-of-rr-ptcl-301934854.html

    PR NEWSWIRE
    21 Sep 2023
    Share Share
    Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib
    Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib

    14 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-announces-china-cde-acceptance-of-new-drug-application-for-golidocitinib-for-relapsed-or-refractory-ptcl-301927562.html

    PR NEWSWIRE
    14 Sep 2023
    Share Share